Pfizer has sold its 11.7% ownership in ViiV Healthcare, a specialist HIV drug developer, to Shionogi for $1.875 billion in cash. The transaction, completed in the first quarter of 2026, reduces Pfizer’s equity exposure to a non‑core business and injects capital that the company plans to deploy in its high‑growth oncology and obesity portfolios.
The divestiture aligns with Pfizer’s broader strategy to sharpen its focus on core therapeutic areas. By freeing up $1.875 billion, the company can accelerate research and development in oncology, where it has recently announced acquisitions such as Metsera, and expand its obesity pipeline, which has seen increasing investment in recent years. CEO Albert Bourla said the move “strengthens our ability to invest in the areas that will drive the next wave of growth.”
ViiV Healthcare, which is majority owned by GSK, reported first‑quarter 2025 sales of approximately £5.5 billion (about $7.4 billion). The company holds roughly 32 % of the global HIV therapy market and is advancing a portfolio of long‑acting injectable treatments that are expected to capture a growing share of the market. The sale simplifies ViiV’s ownership structure, giving Shionogi a 21.7 % stake and potentially accelerating decision‑making for its pipeline.
Shionogi’s share price rose sharply after the announcement, reflecting investor confidence that the increased stake will provide a foothold in a high‑margin, growth‑oriented franchise. Analysts noted that the transaction positions Shionogi to benefit from ViiV’s pipeline of next‑generation HIV therapies, which could drive future revenue growth for the Japanese company.
The transaction also signals Pfizer’s intent to streamline its equity portfolio. By divesting a non‑core holding, Pfizer can reallocate resources to areas where it has a competitive advantage and where it expects higher returns, reinforcing its long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.